ISU Abxis Co., Ltd. (KOSDAQ:086890)

-20.36% (1Y)

Market Cap	182.01B
Revenue (ttm)	60.26B
Net Income (ttm)	14.72B
Shares Out	36.59M
EPS (ttm)	n/a
PE Ratio	12.37
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	119,404
Average Volume	186,680
Open	5,360.00
Previous Close	5,340.00
Day's Range	5,200.00 - 5,370.00
52-Week Range	3,945.00 - 8,000.00
Beta	0.76
RSI	38.54
Earnings Date	Mar 13, 2025

About ISU Abxis

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary inte...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2001
• Employees: 95
• Stock Exchange: KOSDAQ
• Ticker Symbol: 086890

Financial Performance

In 2024, ISU Abxis's revenue was 60.26 billion, an increase of 10.96% compared to the previous year's 54.31 billion. Earnings were 14.72 billion, an increase of 307.63%.